Zsolt Tulassay

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

Brian G. Feagan, William J. Sandborn, Christopher Gasink et al. · New England Journal of Medicine · 2016 · 1.8K citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17

A Comparison of Omeprazole with Ranitidine for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs

Neville D. Yeomans, Zsolt Tulassay, L Juhász et al. · New England Journal of Medicine · 1998 · 768 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial

Stephan R. Targan, Brian G. Feagan, Richard N. Fedorak et al. · Gastroenterology · 2007 · 614 citations

Medicine, Internal Medicine, Pharmacotherapy +8

Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients.

Béla Molnár, András Ladányi, Lenke M. Tanko et al. · PubMed · 2001 · 245 citations

Medicine, Oncology, Pathology +17

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

László Kiss, Tamás Szamosi, Tamás Molnár et al. · Alimentary Pharmacology & Therapeutics · 2011 · 160 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17